Clinical studyThe bimodal mortality pattern of systemic lupus erythematosus☆
References (26)
- et al.
Determination of prognosis in chronic disease illustrated by systemic lupus erythematosus
J Chronic Dis
(1955) - et al.
Abnormalities of delayed hypersensitivity in systemic lupus erythematosus
Am J Med
(1973) Prophylaxis in patients receiving adrenal steroid therapy
J Chronic Dis
(1962)- et al.
The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy A study of 36 necropsy patients
Am J Med
(1975) - et al.
Systemic lupus erythematosus and acute myocardial infarction
Chest
(1973) - et al.
Coronary arteritis, occlusion, and myocardial infarction due to lupus erythematosus
Am Heart J
(1972) - et al.
Presentation of two bone marrow elements; the “Tart” cell and the “L.E.” cell
- et al.
Immunologic factors and clinical activity in systemic lupus erythematosus
N Engl J Med
(1968) - et al.
Systemic lupus erythematosus A statistical evaluation of mortality based on a consecutive series of 299 patients
Arch Intern Med
(1964) - et al.
The natural history of systemic lupus erythematosus by prospective analysis
Medicine (Baltimore)
(1971)
Preliminary criteria for the classification of systemic lupus erythematosus
Bull Rheum Dis
(1971)
Systemic lupus erythematosus and LE cell phenomenon
Postgrad Med
(1954)
Laboratory Diagnostic Procedures in the Rheumatic Diseases
Cited by (890)
Accelerated Atherosclerosis and Management of Cardiovascular Risk in Autoimmune Rheumatic Diseases: An Updated Review
2023, Current Problems in CardiologyMortality and causes of death in systemic lupus erythematosus revisited
2023, European Journal of Internal MedicineMortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large population-based study
2023, European Journal of Internal MedicineSystemic lupus erythematosus and damage: What has changed over the past 20 years?
2023, Best Practice and Research: Clinical RheumatologyTargeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside
2024, Signal Transduction and Targeted Therapy
- ☆
This study was supported by Grant No. 7-144-(70) from the Canadian Arthritis Society.
- 1
From the University of Toronto Rheumatic Disease Unit, Wellesley Hospital, Toronto, Ontario, Canada.
Copyright © 1976 Published by Excerpta Medica Inc.